Exploring Undiscovered Gems in Asia December 2025

Simply Wall St · 2d ago

As global markets navigate a landscape of interest rate adjustments and economic uncertainties, the Asian market presents unique opportunities, particularly in the small-cap sector. With recent shifts in monetary policy and evolving economic indicators, identifying stocks with strong fundamentals and growth potential becomes crucial for investors seeking to uncover undiscovered gems.

Top 10 Undiscovered Gems With Strong Fundamentals In Asia

Name Debt To Equity Revenue Growth Earnings Growth Health Rating
Wuxi Double Elephant Micro Fibre MaterialLtd 5.49% 13.38% 64.10% ★★★★★★
Oriental Precision & EngineeringLtd 32.67% 9.30% 4.58% ★★★★★★
Thai Steel Cable NA 3.35% 17.89% ★★★★★★
Jiangyin Haida Rubber And Plastic 11.87% 8.96% -3.28% ★★★★★★
Nextronics Engineering 20.23% 11.39% 24.54% ★★★★★★
Wholetech System Hitech 14.93% 13.36% 18.63% ★★★★★☆
House of Investments 18.23% 14.46% 47.47% ★★★★★☆
Li Ming Development Construction 183.36% 8.59% 19.98% ★★★★☆☆
Chinyang Holdings 31.98% 7.57% -15.85% ★★★★☆☆
Zhejiang Risun Intelligent TechnologyLtd 51.85% 20.80% -5.94% ★★★★☆☆

Click here to see the full list of 2496 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.

Let's dive into some prime choices out of from the screener.

Advanced Ceramic X (TPEX:3152)

Simply Wall St Value Rating: ★★★★★★

Overview: Advanced Ceramic X Corporation specializes in designing, manufacturing, and selling RF front-end devices and modules for wireless communication applications across Taiwan, China, the United States, and other international markets with a market capitalization of NT$98 billion.

Operations: Advanced Ceramic X generates revenue from the high-frequency integration of components and modules, amounting to NT$1.54 billion.

Advanced Ceramic X, a smaller player in the industry, has shown an impressive earnings growth of 67.6% over the past year, outpacing the broader Communications sector's 8.8%. The company operates debt-free, eliminating concerns over interest payments and showcasing strong financial health with positive free cash flow. Recent figures reveal a net income of NT$77.66 million for Q3 2025, down from NT$98.81 million in the previous year; however, nine-month results show an increase to NT$567.45 million from NT$319.7 million last year, indicating potential resilience despite quarterly fluctuations.

TPEX:3152 Earnings and Revenue Growth as at Dec 2025
TPEX:3152 Earnings and Revenue Growth as at Dec 2025

Brillian Network & Automation Integrated System (TPEX:6788)

Simply Wall St Value Rating: ★★★★★★

Overview: Brillian Network & Automation Integrated System Co. (TPEX:6788) specializes in providing integrated network and automation solutions, with a market capitalization of NT$11.27 billion.

Operations: Brillian Network & Automation Integrated System Co. generates revenue primarily through its subsidiary, Brillian Network & Automation Integrated System Co. Ltd., contributing NT$1.73 billion, and Kunshan Xinwulian Electronic Communication Co., Ltd., adding NT$744.52 million to the total revenue stream.

Brillian Network & Automation Integrated System, a promising player in the semiconductor space, has shown impressive earnings growth of 58.9% over the past year, outpacing the industry's 2.5%. Trading at 27.1% below its estimated fair value suggests potential for upside. The company is debt-free and boasts high-quality earnings, enhancing its financial stability. Recent results highlight robust net income of TWD 164 million for Q3 2025 compared to TWD 138 million last year, with basic EPS rising to TWD 4.25 from TWD 3.94. Its free cash flow remains positive at US$692 million as of September this year, reflecting strong operational efficiency.

TPEX:6788 Debt to Equity as at Dec 2025
TPEX:6788 Debt to Equity as at Dec 2025

Fukuda Denshi (TSE:6960)

Simply Wall St Value Rating: ★★★★★★

Overview: Fukuda Denshi Co., Ltd. is a company that manufactures and sells medical instruments both in Japan and internationally, with a market capitalization of ¥199.31 billion.

Operations: Fukuda Denshi generates revenue primarily from Treatment Devices, contributing ¥62.79 billion, followed by Consumables at ¥39.83 billion. Biometrics Equipment and Biological Information Monitoring add ¥27.73 billion and ¥9.14 billion, respectively, to the total revenue stream.

Fukuda Denshi, a noteworthy player in the medical equipment sector, has shown robust financial health with earnings growing by 11% over the past year, outpacing industry growth of 3%. The company’s debt to equity ratio improved from 1.4 to 1 over five years, indicating better financial management. Trading at about 26% below its estimated fair value suggests it could be undervalued relative to peers. Recent announcements include a dividend increase to ¥65 per share and projected net sales of ¥137 billion for the fiscal year ending March 2026, reinforcing its commitment to shareholder returns and strong operational performance.

TSE:6960 Earnings and Revenue Growth as at Dec 2025
TSE:6960 Earnings and Revenue Growth as at Dec 2025

Next Steps

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.